Alzheimer's Disease (AD)Phase 1NCT07568041
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
A Phase 1 study testing 8M2D in people with Alzheimer's Disease (AD), run by Cenna Biosciences Inc..
Trial summary
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people. Hypothesis: Researchers believe that 8M2D can be administered safely to healthy adults and to people with early Alzheimer's disease, and that it may… Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer's Disease (AD)
- What is being tested?
- 8M2D
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 54 participants
- Where
- No sites listed yet
- Study dates
- 15 Sep 2026to Dec 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Part I (Single Ascending Dose) and Part II (Multiple Ascending Dose):
- Voluntarily consents to participate in this trial and provides written informed consent before the start of any trial assessments.
- Healthy male and female adults, 18 and 55 years of age (inclusive).
- Participants with a body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 (inclusive) and weigh a minimum of 50 kg.
- Participants with a normal 12-lead ECG at Screening.
- Participant has normal renal function.
Show all 22Show fewer
- Females participants must meet one of the following criteria:
- Females must either be of non-childbearing potential, or if of childbearing potential, must agree to use contraceptives throughout the study period and have a negative pregnancy test at both Screening and Check-in (Day -1).
- Males with a sexual partner who is a female of childbearing potential must be surgically sterile, or agree to use condoms with spermicide or abstain from sexual intercourse, starting from Screening until 90 days after the last dose of the trial medication.
- Participant is willing and able to complete all trial assessments in compliance with the protocol and is able to remain in the inpatient treatment unit for the entire duration of the confinement period and return for outpatient visits.
- Part III Alzheimer's Disease:
- Participant is able to provide written informed consent prior to the performance of any trial -specific procedures.
- Male or female participants with early Alzheimer's disease between 55 and 80 years of age (inclusive) in good health as determined by the Investigator.
- Participants with a BMI of ≥ 18.0 and ≤ 32.0 kg/m2 (inclusive) and weigh a minimum of 50 kg.
- Participants with a 12-lead ECG at screening which, in the opinion of the Investigator, has no abnormalities that compromise participant's safety in this study.
- Females participants must meet one of the following criteria:
- Females must either be of non-childbearing potential, or if of childbearing potential, must agree to use contraceptives throughout the study period and have a negative pregnancy test at both Screening and Check-in (Day -1).
- Males with a sexual partner who is a female of childbearing potential must be surgically sterile, or agree to use condoms with spermicide or abstain from sexual intercourse, starting from Screening until 90 days after the last dose of the trial medication.
- Participant is willing and able to complete all trial assessments in compliance with the protocol and is able to remain in the inpatient treatment unit for the entire duration of the confinement period and return for outpatient visits.
- Participant meets the diagnostic criteria of mild cognitive impairment (MCI) of probable Alzheimer's disease consistent with National Institute On Aging - Alzheimer's Association (NIA-AA) research framework.
- Participant with a qualifying amyloid score.
- Participant with a Mini-Mental State Examination (MMSE) score between 20 and 28 inclusive at screening and baseline.
Who cannot join
- Part I (Single Ascending Dose) and Part II (Multiple Ascending Dose):
- History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the trial results.
- Participant has abnormal laboratory values detected at Screening or on clinic admission (Day -1) that suggest a clinically significant underlying disease.
- Participant who shows evidence of suicidal ideation as assessed by the C-SSRS at screening and at Day -1 or history of suicide attempt (lifetime).
- Participant with positive serology for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) at Screening.
- Participant smokes cigarettes or uses other nicotine-containing products in the past 3 months prior to Screening.
Show all 22Show fewer
- Participant with regular alcohol consumption within 6 months prior to the trial defined as an average weekly intake of > 20 units for males or > 16 units for females (8g ethanol = 1 unit).
- Participant tests positive in the urine test for alcohol, cotinine, and/or screen for drugs of abuse at the time of screening or Day -1.
- Participant with a history of drug abuse according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM V criteria or later) within the 2 years prior to study entry.
- Participation in any clinical trial and/or recipient of investigational trial medication within 90 days prior to the first dose of 8M2D.
- Participant with a loss of ≥ 500 mL (1 unit) of blood within 90 days prior to receiving the first dose of 8M2D.
- In addition to the above criteria, those judged by the Investigator as not suitable for participating in this clinical trial
- Part III Alzheimer's Disease:
- Participant with history or presence of any uncontrolled systemic disease (e.g., hypertension (systolic BP ≥ 150 mmHg/diastolic BP ≥ 100 mmHg), diabetes mellitus (HbA1c ≥ 8% at the time of screening) etc.).
- Participant with history or presence of unstable or clinically significant cardiovascular (e.g., myocardial infarction), kidney, or liver disease.
- Participant with any active or unstable clinically significant medical or psychiatric condition as judged by the Investigator.
- Participant who has current serious or unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the Investigator's opinion, could interfere with the analyses of safety and efficacy in this trial.
- Participant with any evidence of a condition other than AD that may affect cognition such as other dementias, stroke, brain damage, autoimmune disorders (e.g. multiple sclerosis) or infections with neurological sequelae.
- Participant with history within the past 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate specific antigen post-resection.
- Participant with history of intracranial hemorrhage, cerebrovascular aneurysm, or arteriovenous malformation, carotid artery occlusion, stroke, or epilepsy.
- Participant who shows evidence of suicidal ideation as assessed by the C-SSRS at screening and at Day -1 or history of suicide attempt (lifetime).
- Participant with positive serology for HBsAg, HBcAb, HCV, or HIV at Screening.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Phase Ia (SAD/MAD), Randomized, Double-Blind, Placebo-Controlled Trial and Phase Ib Open-Label Trial to Evaluate Safety, Tolerability, PK, and Exploratory Immunogenicity of Single and Multiple Doses of 8M2D in Healthy Participants and Early AD Participants.
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
Hypothesis: Researchers believe that 8M2D can be administered safely to healthy adults and to people with early Alzheimer's disease, and that it may reduce levels of amyloid beta. Amyloid beta is a protein that builds up in the brains of people with Alzheimer's disease and is thought to contribute to its progression.
Read more
The study will be conducted in three parts. In the first two parts, healthy volunteers will receive either a single dose or multiple doses of 8M2D so researchers can understand how the drug moves through the body and whether it causes any side effects. In the third part, a small group of people with early Alzheimer's disease will receive multiple doses so researchers can also begin to assess whether the drug has any effect on amyloid beta levels.
Doses will be increased gradually and carefully. An independent safety board will review safety information before any dose increase is allowed. The information gathered in this study will be used to identify the appropriate dose of 8M2D and to help design future studies in people with Alzheimer's disease.
Read the detailed description
Trial Rationale: This is a three-part Phase 1a/b clinical trial. Phase Ia is a first-in-human (FIH), 2-part (Part I [SAD] and Part II [MAD]) clinical trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and exploratory immunogenicity of single and multiple doses of 8M2D in healthy participants. Phase Ib will consist of Part III (Alzheimer's Disease [AD]), designed to evaluate the safety, tolerability, PK, exploratory immunogenicity, and pharmacodynamics (PD) of multiple doses of 8M2D in participants with early AD.
Data from this trial will be used to identify doses of 8M2D that show safety and tolerability and PD effects on amyloid beta (Aβ), to aid in the design of future trials in patients with AD. Prior to this trial, 8M2D has not been administered to humans. Safety and tolerability evaluations will be conducted over a range of single and multiple doses of 8M2D and dose escalation will not proceed until safety and tolerability data and PK parameters from previous doses have been reviewed by an independent Data and Safety Monitoring Board (DSMB).
This trial will aim to assess a maximum-tolerated dose (MTD), or a maximum feasible dose (based on tolerability of the subcutaneous [SC] injections), or a maximum pharmacologically active dose, based on safety, tolerability and PK data as well as on model-based prediction of the anticipated Aβ lowering. The data generated in this trial will be used to help design subsequent clinical trials in participants with early AD.
- Conditions
- Alzheimer's Disease (AD)
- Being tested
- 8M2D, Placebo
- Keywords
- Alzheimer's disease, amyloid beta, Alzheimer's disease treatment, Alzheimer's disease prevention, Phase 1a/b clinical trial, Single Ascending Dose, Multiple Ascending Dose, first-in-human, safety, tolerability, and pharmacokinetics, exploratory immunogenicity
- Medical subject headings
- Alzheimer Disease, Plaque, Amyloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
8M2DDrug
8M2D administered by subcutaneous injection. Evaluated across single ascending doses (Part I) and multiple ascending doses (Part II) in healthy participants, and as multiple doses in participants with early Alzheimer's disease (Part III).
PlaceboDrug
Matching placebo administered by subcutaneous injection in healthy participants across the single ascending dose (Part I) and multiple ascending dose (Part II) parts of the study.
| Study group | Role | What they receive |
|---|---|---|
| 8M2D Single Ascending Dose (SAD) - healthy participants, Part I | Experimental | Part I (SAD) is a Phase Ia, First-in-Human, single-center, randomized, double-blind, placebo-controlled, dose escalating, SAD part of the clinical trial designed to evaluate the safety, tolerability, PK, and exploratory immunogenicity of single doses of 8M2D in healthy adult participants.
Part I (SAD) will evaluate up to 5 dose levels of 8M2D. Approximately 30 eligible participants will be enrolled and assigned to 1 of 5 cohorts, with 6 participants per SAD cohort. In each of the SAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive a single SC dose of 8M2D or matching placebo on Day 1. The intervention will be administered by subcutaneous injection. Receives: Drug: 8M2D |
| 8M2D Multiple Ascending Dose (MAD) - healthy participants, Part II | Experimental | Part II (MAD) is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, dose escalating, MAD part of the clinical trial designed to evaluate the safety, tolerability, PK, and exploratory immunogenicity of multiple doses of 8M2D in healthy adult participants.
Part II (MAD) will evaluate up to 3 dose levels of 8M2D. Approximately 18 eligible participants will be enrolled and assigned to 1 of 3 cohorts, with 6 participants per MAD cohort. In each of the MAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive once-daily (QD) SC doses of 8M2D or matching placebo on Days 1 to 7. The intervention will be administered by subcutaneous injection. Receives: Drug: 8M2D |
| Placebo - healthy participants (Parts I & II combined) | Placebo comparator | Study Parts I and II each include a placebo arm.
Part I (SAD) will evaluate up to 5 dose levels of 8M2D. Approximately 30 eligible participants will be enrolled and assigned to 1 of 5 cohorts, with 6 participants per SAD cohort. In each of the SAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive a single SC dose of 8M2D or matching placebo on Day 1.
Part II (MAD) will evaluate up to 3 dose levels of 8M2D. Approximately 18 eligible participants will be enrolled and assigned to 1 of 3 cohorts, with 6 participants per MAD cohort. In each of the MAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive once-daily (QD) SC doses of 8M2D or matching placebo on Days 1 to 7.
Placebo will be administered by subcutaneous injection. Receives: Drug: Placebo |
| 8M2D Multiple Dose (Open-Label) - Early Alzheimer's Disease - Part III | Experimental | Part III (AD) will consist of a single cohort of participants with early AD. Approximately 6 eligible participants with early AD will be enrolled into a single cohort and will receive QD SC doses of 8M2D from Days 1 to 14. The intervention will be administered by subcutaneous injection. Receives: Drug: 8M2D |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants reporting treatment-emergent adverse events
A treatment-emergent adverse event is defined as any adverse event that has an onset on or after the first dose of the trial medication, or any pre-existing condition that has worsened on or after the first dose of the trial intervention.
Measured: Baseline to Day 44
Number of participants reporting treatment-emergent adverse events that require discontinuation of therapy due to intolerable side effects
Evaluation of the number of participants withdrawn from study medication due to treatment-emergent adverse events.
Measured: Baseline to Day 14
Number of participants reporting injection site reactions
Evaluation of skin reactions at the injection site, including pain, itching, and swelling or redness around the injection site.
Measured: Baseline to Day 22
Number of participants demonstrating abnormal laboratory findings
Evaluation of laboratory results outside the documented normal range as defined by the clinical laboratory.
Measured: Baseline to Day 14
Number of participants demonstrating abnormal vital signs
Evaluation of absolute vital sign value and the changes from baseline that are outside the normal range.
Measured: Baseline to Day 22
Number of participants demonstrating abnormal vital electrocardiogram (ECG) parameters
Evaluation of 12-lead ECG parameters.
Measured: Baseline to Day 15
Number of participants demonstrating adverse changes in physical and/or neurologic examinations
Evaluation of the physical and/or neurological examinations conducted by site clinicians during the study period.
Measured: Baseline to Day 22
Number of participants reporting changes in Columbia-Suicide Severity Rating Scale (C-SSRS) from baseline
The C-SSRS is a suicidal ideation and behavior rating scale to evaluate suicide risk. The total score ranges from 0 (no ideation is present) to 5 (active suicidal ideation with specific plan and intent).
Measured: Baseline to Day 22
Maximum observed concentration (Cmax) of 8M2D
Maximum concentration of 8M2D, determined directly from individual concentration-time data determined through plasma and CSF analysis.
Measured: Baseline to Day 14
Time to maximum observed concentration (tmax) of 8M2D
Time of the maximum concentration of 8M2D determined through plasma and CSF analysis.
Measured: Baseline to Day 14
Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC-last) of 8M2D
Evaluated from time-zero to the time of the last quantifiable concentration of 8M2D determined through plasma and CSF analysis.
Measured: Baseline to Day 14
Terminal phase half-life (t1/2)
The observed terminal half-life of 8M2D determined through plasma and CSF analysis.
Measured: Baseline to Day 14
Area under the concentration-time curve from time 0 to infinity (AUC-inf)
Area under the concentration-time curve from time-zero extrapolated to infinity.
Measured: Baseline to Day 14
Assessment of changes from baseline after 14 days of dosing in plasma and CSF biomarkers of AD [such as Aβ42, Aβ40, p-tau217, and np-tau217
Evaluation of biomarkers of AD through plasma and CSF collected from all participants in Part III (AD) of the study.
Measured: Baseline to Day 14
Secondary outcomes (1)
Assessment of the presence of anti-8M2D antibody in participants of all cohorts.
Evaluation of anti-8M2D antibody presence in blood samples collected from all participants.
Measured: Baseline to Day 22
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2026
- Study start15 Sep 2026 (estimated)
- Primary completionSep 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's Disease (AD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- Phase Ia is a first-in-human, 2-part (Part I single ascending dose and Part II multiple-ascending dose) clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and exploratory immunogenicity of single and multiple doses of 8M2D in healthy participants. Phase Ib will consist of Part III (Alzheimer's Disease \[AD\]), designed to evaluate the safety, tolerability, PK, exploratory immunogenicity, and pharmacodynamics of multiple doses of 8M2D in participants with early AD.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cenna Biosciences Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Nazneen Dewji, PhD, Principal investigator, Cenna Biosciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07568041
- Sponsor's protocol ID
- CN101
- Status last verified
- Apr 2026
- First submitted
- 20 Apr 2026
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase Ia (SAD/MAD), Randomized, Double-Blind, Placebo-Controlled Trial and Phase Ib Open-Label Trial to Evaluate Safety, Tolerability, PK, and Exploratory Immunogenicity of Single and Multiple Doses of 8M2D in Healthy Participants and Early AD Participants.
- ClinicalTrials.gov ID
- NCT07568041
- Acronym / sponsor ID
- CN101
- Conditions
- Alzheimer's Disease (AD)
- Keywords
- Alzheimer's disease, amyloid beta, Alzheimer's disease treatment, Alzheimer's disease prevention, Phase 1a/b clinical trial, Single Ascending Dose, Multiple Ascending Dose, first-in-human
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Cenna Biosciences Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Sep 2026 (estimated)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 5 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
Hypothesis: Researchers believe that 8M2D can be administered safely to healthy adults and to people with early Alzheimer's disease, and that it may reduce levels of amyloid beta. Amyloid beta is a protein that builds up in the brains of people with Alzheimer's disease and is thought to contribute to its progression.
The study will be conducted in three parts. In the first two parts, healthy volunteers will receive either a single dose or multiple doses of 8M2D so researchers can understand how the drug moves through the body and whether it causes any side effects. In the third part, a small group of people with early Alzheimer's disease will receive multiple doses so researchers can also begin to assess whether the drug has any effect on amyloid beta levels.
Doses will be increased gradually and carefully. An independent safety board will review safety information before any dose increase is allowed. The information gathered in this study will be used to identify the appropriate dose of 8M2D and to help design future studies in people with Alzheimer's disease.
Detailed description
Trial Rationale: This is a three-part Phase 1a/b clinical trial. Phase Ia is a first-in-human (FIH), 2-part (Part I [SAD] and Part II [MAD]) clinical trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), and exploratory immunogenicity of single and multiple doses of 8M2D in healthy participants. Phase Ib will consist of Part III (Alzheimer's Disease [AD]), designed to evaluate the safety, tolerability, PK, exploratory immunogenicity, and pharmacodynamics (PD) of multiple doses of 8M2D in participants with early AD.
Data from this trial will be used to identify doses of 8M2D that show safety and tolerability and PD effects on amyloid beta (Aβ), to aid in the design of future trials in patients with AD. Prior to this trial, 8M2D has not been administered to humans. Safety and tolerability evaluations will be conducted over a range of single and multiple doses of 8M2D and dose escalation will not proceed until safety and tolerability data and PK parameters from previous doses have been reviewed by an independent Data and Safety Monitoring Board (DSMB).
This trial will aim to assess a maximum-tolerated dose (MTD), or a maximum feasible dose (based on tolerability of the subcutaneous [SC] injections), or a maximum pharmacologically active dose, based on safety, tolerability and PK data as well as on model-based prediction of the anticipated Aβ lowering. The data generated in this trial will be used to help design subsequent clinical trials in participants with early AD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Phase Ia is a first-in-human, 2-part (Part I single ascending dose and Part II multiple-ascending dose) clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and exploratory immunogenicity of single and multiple doses of 8M2D in healthy participants. Phase Ib will consist of Part III (Alzheimer's Disease [AD]), designed to evaluate the safety, tolerability, PK, exploratory immunogenicity, and pharmacodynamics of multiple doses of 8M2D in participants with early AD.
| Arm | Type | Receives |
|---|---|---|
| 8M2D Single Ascending Dose (SAD) - healthy participants, Part I | Experimental | Drug: 8M2DPart I (SAD) is a Phase Ia, First-in-Human, single-center, randomized, double-blind, placebo-controlled, dose escalating, SAD part of the clinical trial designed to evaluate the safety, tolerability, PK, and exploratory immunogenicity of single doses of 8M2D in healthy adult participants. Part I (SAD) will evaluate up to 5 dose levels of 8M2D. Approximately 30 eligible participants will be enrolled and assigned to 1 of 5 cohorts, with 6 participants per SAD cohort. In each of the SAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive a single SC dose of 8M2D or matching placebo on Day 1. The intervention will be administered by subcutaneous injection. |
| 8M2D Multiple Ascending Dose (MAD) - healthy participants, Part II | Experimental | Drug: 8M2DPart II (MAD) is a Phase Ia, single-center, randomized, double-blind, placebo-controlled, dose escalating, MAD part of the clinical trial designed to evaluate the safety, tolerability, PK, and exploratory immunogenicity of multiple doses of 8M2D in healthy adult participants. Part II (MAD) will evaluate up to 3 dose levels of 8M2D. Approximately 18 eligible participants will be enrolled and assigned to 1 of 3 cohorts, with 6 participants per MAD cohort. In each of the MAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive once-daily (QD) SC doses of 8M2D or matching placebo on Days 1 to 7. The intervention will be administered by subcutaneous injection. |
| Placebo - healthy participants (Parts I & II combined) | Placebo comparator | Drug: PlaceboStudy Parts I and II each include a placebo arm. Part I (SAD) will evaluate up to 5 dose levels of 8M2D. Approximately 30 eligible participants will be enrolled and assigned to 1 of 5 cohorts, with 6 participants per SAD cohort. In each of the SAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive a single SC dose of 8M2D or matching placebo on Day 1. Part II (MAD) will evaluate up to 3 dose levels of 8M2D. Approximately 18 eligible participants will be enrolled and assigned to 1 of 3 cohorts, with 6 participants per MAD cohort. In each of the MAD cohorts, 6 participants will be randomized in a 4:2 ratio (4 active: 2 placebo) to receive once-daily (QD) SC doses of 8M2D or matching placebo on Days 1 to 7. Placebo will be administered by subcutaneous injection. |
| 8M2D Multiple Dose (Open-Label) - Early Alzheimer's Disease - Part III | Experimental | Drug: 8M2DPart III (AD) will consist of a single cohort of participants with early AD. Approximately 6 eligible participants with early AD will be enrolled into a single cohort and will receive QD SC doses of 8M2D from Days 1 to 14. The intervention will be administered by subcutaneous injection. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (22 listed)
- Voluntarily consents to participate in this trial and provides written informed consent before the start of any trial assessments.
- Healthy male and female adults, 18 and 55 years of age (inclusive).
- Participants with a body mass index (BMI) ≥ 18 and ≤ 32 kg/m2 (inclusive) and weigh a minimum of 50 kg.
- Participants with a normal 12-lead ECG at Screening.
- Participant has normal renal function.
Key exclusion criteria (22 listed)
- History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the trial results.
- Participant has abnormal laboratory values detected at Screening or on clinic admission (Day -1) that suggest a clinically significant underlying disease.
- Participant who shows evidence of suicidal ideation as assessed by the C-SSRS at screening and at Day -1 or history of suicide attempt (lifetime).
- Participant with positive serology for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) at Screening.
- Participant smokes cigarettes or uses other nicotine-containing products in the past 3 months prior to Screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 8M2D8M2D administered by subcutaneous injection. Evaluated across single ascending doses (Part I) and multiple ascending doses (Part II) in healthy participants, and as multiple doses in participants with early Alzheimer's disease (Part III). | Drug | 8M2D Multiple Ascending Dose (MAD) - healthy participants, Part II, 8M2D Multiple Dose (Open-Label) - Early Alzheimer's Disease - Part III, 8M2D Single Ascending Dose (SAD) - healthy participants, Part I |
| PlaceboMatching placebo administered by subcutaneous injection in healthy participants across the single ascending dose (Part I) and multiple ascending dose (Part II) parts of the study. | Drug | Placebo - healthy participants (Parts I & II combined) |
Primary outcome
Number of participants reporting treatment-emergent adverse events
Time frame: Baseline to Day 44
A treatment-emergent adverse event is defined as any adverse event that has an onset on or after the first dose of the trial medication, or any pre-existing condition that has worsened on or after the first dose of the trial intervention.
Number of participants reporting treatment-emergent adverse events that require discontinuation of therapy due to intolerable side effects
Time frame: Baseline to Day 14
Evaluation of the number of participants withdrawn from study medication due to treatment-emergent adverse events.
Number of participants reporting injection site reactions
Time frame: Baseline to Day 22
Evaluation of skin reactions at the injection site, including pain, itching, and swelling or redness around the injection site.
Number of participants demonstrating abnormal laboratory findings
Time frame: Baseline to Day 14
Evaluation of laboratory results outside the documented normal range as defined by the clinical laboratory.
Number of participants demonstrating abnormal vital signs
Time frame: Baseline to Day 22
Evaluation of absolute vital sign value and the changes from baseline that are outside the normal range.
Number of participants demonstrating abnormal vital electrocardiogram (ECG) parameters
Time frame: Baseline to Day 15
Evaluation of 12-lead ECG parameters.
Number of participants demonstrating adverse changes in physical and/or neurologic examinations
Time frame: Baseline to Day 22
Evaluation of the physical and/or neurological examinations conducted by site clinicians during the study period.
Number of participants reporting changes in Columbia-Suicide Severity Rating Scale (C-SSRS) from baseline
Time frame: Baseline to Day 22
The C-SSRS is a suicidal ideation and behavior rating scale to evaluate suicide risk. The total score ranges from 0 (no ideation is present) to 5 (active suicidal ideation with specific plan and intent).
Maximum observed concentration (Cmax) of 8M2D
Time frame: Baseline to Day 14
Maximum concentration of 8M2D, determined directly from individual concentration-time data determined through plasma and CSF analysis.
Time to maximum observed concentration (tmax) of 8M2D
Time frame: Baseline to Day 14
Time of the maximum concentration of 8M2D determined through plasma and CSF analysis.
Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC-last) of 8M2D
Time frame: Baseline to Day 14
Evaluated from time-zero to the time of the last quantifiable concentration of 8M2D determined through plasma and CSF analysis.
Terminal phase half-life (t1/2)
Time frame: Baseline to Day 14
The observed terminal half-life of 8M2D determined through plasma and CSF analysis.
Area under the concentration-time curve from time 0 to infinity (AUC-inf)
Time frame: Baseline to Day 14
Area under the concentration-time curve from time-zero extrapolated to infinity.
Assessment of changes from baseline after 14 days of dosing in plasma and CSF biomarkers of AD [such as Aβ42, Aβ40, p-tau217, and np-tau217
Time frame: Baseline to Day 14
Evaluation of biomarkers of AD through plasma and CSF collected from all participants in Part III (AD) of the study.
1 secondary outcome
Assessment of the presence of anti-8M2D antibody in participants of all cohorts.
Time frame: Baseline to Day 22
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer's Disease (AD)
RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Not yet recruiting
Negotiation Training for Family Caregivers of People With Alzheimer's Disease
Alzheimer's Disease (AD), Dementia
RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Recruiting
Combating Alzheimer's Through Sleep and Exercise
Dementia, Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nazneen Dewji, PhD principal investigator
Cenna Biosciences
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing 8M2D in people with Alzheimer's Disease (AD), run by Cenna Biosciences Inc..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 22 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kimberly Schafer, MS (619-912-7475, kims@cennabiosciences.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants reporting treatment-emergent adverse events (time frame: Baseline to Day 44). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.